Dermata Therapeutics (DRMA) is a pre-revenue clinical-stage/early-commercial-stage entity that pivoted in September 2025 from prescription dermatology drug development to OTC skincare products. Under a liquidation lens, recovery to equity is marginally positive but thin: MFFAIS reports CLV/LLV/OLV of approximately $6.3M, broadly consistent with book equity of $6.2M, driven almost entirely by cash. Total assets of $7.9M consist overwhelmingly of cash and cash equivalents ($7.5M, ~96% of total assets), with the remainder in prepaid expenses ($0.3M) and other current assets ($0.05M). There are no hard assets, no inventory on the balance sheet as of year-end, no PP&E, and no separately tagged intangibles. The liability stack is modest at $1.6M, comprising accounts payable ($0.5M), accrued liabilities ($1.2M), and employee-related accruals ($1.0M, partially overlapping). Applying the liquidation lens: cash at 100% yields ~$7.5M; prepaid at zero recovery (non-transferable insurance, deposits) yields nothing; liabilities at face absorb ~$1.6M. Net liquidation value to equity approximates $5.9M–$6.3M, broadly in line with stated book equity. Accumulated deficit stands at $73.2M. The company burned $7.8M in operations during FY2025 against $12.2M raised through equity issuances and warrant exercises; cash increased by $4.4M year-over-year to $7.5M at 12/31/2025. Subsequent to year-end, the company issued 824K additional shares via ATM for ~$2.0M net proceeds, exhausting ATM capacity, and all December 2025 pre-funded warrants (537,750 shares) were exercised. Cash runway is materially extended relative to the prior 10-Q disclosure that projected into Q2 2026, but the company still carries a going concern qualifier given no revenue and continued operating losses. The Villani license agreement dispute was resolved by termination effective February 15, 2026; no financial payments were accrued as management assessed no probable loss. The 5.4M warrants outstanding (excluding pre-funded) represent a large overhang relative to 2.7M diluted shares outstanding but are largely classified as equity and out-of-the-money at the $2.32 closing price. Milestone obligations under the Villani license (up to $40.5M) are now moot post-termination. No debt, no operating leases, no pension obligations. The filing does not separately tag inventory or PP&E, consistent with the company having neither on the balance sheet.
▼ Community Notes